3-Oxo-hexahydro-1H-isoindole-4-carboxylic Acid as a Drug Chiral Bicyclic Scaffold: Structure-Based Design and Preparation of Conformationally Constrained Covalent and Noncovalent Prolyl Oligopeptidase Inhibitors.

Bicyclic chiral scaffolds are privileged motifs in medicinal chemistry. Over the years, we have reported covalent bicyclic prolyl oligopeptidase inhibitors that were highly selective for POP over a number of homologous proteins. Herein, we wish to report the structure-based design and synthesis of a novel class of POP inhibitors based on hexahydroisoindoles. A docking study guided the selection of structures for synthesis. The stereochemistry, decoration, and position within the molecule of the bicyclic scaffolds were assessed virtually. Following the synthesis of the best candidates, in vitro assays revealed that one member of this chemical series was more active than any of our previous inhibitors with a Ki of 1.0 nM. Additional assays also showed that the scaffold of this potent inhibitor, in contrast to one of our previously reported chemical series, is highly metabolically stable, despite the foreseen potential sites of metabolism. Interestingly, computer docking calculations accurately predicted the optimal features of the inhibitors.

[1]  A. Stepan,et al.  Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. , 2011, Chemical research in toxicology.

[2]  N. Moitessier,et al.  Solvent effect in diastereoselective intramolecular Diels–Alder reactions , 2015 .

[3]  Z. Zuo,et al.  Regioselective biotransformation of CNS drugs and its clinical impact on adverse drug reactions , 2012, Expert opinion on drug metabolism & toxicology.

[4]  Louis J. Farrugia,et al.  WinGX suite for small-molecule single-crystal crystallography , 1999 .

[5]  Christopher R. Corbeil,et al.  Docking Ligands into Flexible and Solvated Macromolecules, 1. Development and Validation of FITTED 1.0 , 2007, J. Chem. Inf. Model..

[6]  Wei Duan,et al.  Drug Bioactivation Covalent Binding to Target Proteins and Toxicity Relevance , 2005, Drug metabolism reviews.

[7]  Nathanael Weill,et al.  Docking Ligands into Flexible and Solvated Macromolecules, 7. Impact of Protein Flexibility and Water Molecules on Docking-Based Virtual Screening Accuracy , 2014, J. Chem. Inf. Model..

[8]  P. V. von Hippel,et al.  Calculation of protein extinction coefficients from amino acid sequence data. , 1989, Analytical biochemistry.

[9]  G. Sheldrick A short history of SHELX. , 2008, Acta crystallographica. Section A, Foundations of crystallography.

[10]  J. G. Robertson,et al.  Mechanistic basis of enzyme-targeted drugs. , 2005, Biochemistry.

[11]  C. Pham-Huy,et al.  Chiral Drugs: An Overview , 2006, International journal of biomedical science : IJBS.

[12]  Nicolas Moitessier,et al.  Constrained peptidomimetics reveal detailed geometric requirements of covalent prolyl oligopeptidase inhibitors. , 2009, Journal of medicinal chemistry.

[13]  Tanya Singh,et al.  AADS - An Automated Active Site Identification, Docking, and Scoring Protocol for Protein Targets Based on Physicochemical Descriptors , 2011, J. Chem. Inf. Model..

[14]  Erik A. A. Wallén,et al.  Binding kinetics and duration of in vivo action of novel prolyl oligopeptidase inhibitors. , 2006, Biochemical pharmacology.

[15]  N. Moitessier,et al.  Metabolic Instability of Cyanothiazolidine‐Based Prolyl Oligopeptidase Inhibitors: a Structural Assignment Challenge and Potential Medicinal Chemistry Implications , 2015, ChemMedChem.

[16]  B. O'connor,et al.  Identification and Initial Characterization of a N-Benzyloxycarbonyl-Prolyl-Prolinal (Z-Pro-Prolinal)-Insensitive 7-(N-Benzyloxycarbonyl-Glycyl-Prolyl-Amido)-4-Methylcoumarin (Z-Gly-Pro-NH-Mec)-Hydrolysing Peptidase in Bovine Serum , 1997 .

[17]  M. Potashman,et al.  Covalent modifiers: an orthogonal approach to drug design. , 2009, Journal of medicinal chemistry.

[18]  A. Kalgutkar,et al.  Drug discovery for a new generation of covalent drugs , 2012, Expert opinion on drug discovery.

[19]  L. Guterman,et al.  COVALENT DRUGS FORM LONG-LIVED TIES: IRREVERSIBLE INHIBITORS may provide unique benefits in drug development , 2011 .

[20]  J F Morrison,et al.  Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. , 1969, Biochimica et biophysica acta.

[21]  V. Fülöp,et al.  Electrostatic Effects and Binding Determinants in the Catalysis of Prolyl Oligopeptidase , 2002, The Journal of Biological Chemistry.

[22]  Adrian Whitty,et al.  The resurgence of covalent drugs , 2011, Nature Reviews Drug Discovery.

[23]  J. Mascareñas,et al.  Palladium-catalyzed [4+3] intramolecular cycloaddition of alkylidenecyclopropanes and dienes. , 2007, Journal of the American Chemical Society.

[24]  A. Lambeir Translational research on prolyl oligopeptidase inhibitors: the long road ahead , 2011, Expert opinion on therapeutic patents.

[25]  T. Tarragó,et al.  Low molecular weight inhibitors of Prolyl Oligopeptidase: a review of compounds patented from 2003 to 2010 , 2011, Expert opinion on therapeutic patents.

[26]  K N Houk,et al.  Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins. , 2009, Journal of medicinal chemistry.

[27]  J. Hakkarainen,et al.  Brain pharmacokinetics of two prolyl oligopeptidase inhibitors, JTP-4819 and KYP-2047, in the rat. , 2011, Basic & clinical pharmacology & toxicology.

[28]  V. Fülöp,et al.  P2-substituted N-acylprolylpyrrolidine inhibitors of prolyl oligopeptidase: biochemical evaluation, binding mode determination, and assessment in a cellular model of synucleinopathy. , 2012, Journal of medicinal chemistry.

[29]  V. Fülöp,et al.  Inhibition of prolyl oligopeptidase with a synthetic unnatural dipeptide. , 2010, Bioorganic & medicinal chemistry.

[30]  Nicolas Moitessier,et al.  Virtual screening and computational optimization for the discovery of covalent prolyl oligopeptidase inhibitors with activity in human cells. , 2012, Journal of medicinal chemistry.

[31]  B. Cravatt,et al.  Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. , 2010, Future medicinal chemistry.

[32]  Valérie Campagna-Slater,et al.  Integrating Medicinal Chemistry, Organic/Combinatorial Chemistry, and Computational Chemistry for the Discovery of Selective Estrogen Receptor Modulators with Forecaster, a Novel Platform for Drug Discovery , 2012, J. Chem. Inf. Model..

[33]  V. Baekelandt,et al.  A prolyl oligopeptidase inhibitor, KYP‐2047, reduces α‐synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease , 2012, British journal of pharmacology.

[34]  J. Tenorio-Laranga,et al.  Prolyl oligopeptidase colocalizes with α-synuclein, β-amyloid, tau protein and astroglia in the post-mortem brain samples with Parkinson’s and Alzheimer’s diseases , 2013, Neuroscience.

[35]  L. Juillerat-Jeanneret,et al.  Inhibitors of prolyl oligopeptidases for the therapy of human diseases: defining diseases and inhibitors. , 2010, Journal of medicinal chemistry.

[36]  Ernesto Callegari,et al.  A comprehensive listing of bioactivation pathways of organic functional groups. , 2005, Current drug metabolism.

[37]  F. Fleming,et al.  Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore. , 2010, Journal of medicinal chemistry.

[38]  A. Lambeir Interaction of prolyl oligopeptidase with α-synuclein. , 2011, CNS & neurological disorders drug targets.

[39]  F. Checler,et al.  S 17092-1, a highly potent, specific and cell permeant inhibitor of human proline endopeptidase. , 1999, Biochemical and biophysical research communications.

[40]  Y. Iwamoto,et al.  A novel prolyl endopeptidase inhibitor, JTP-4819, with potential for treating Alzheimer's disease , 1997, Behavioural Brain Research.